Beaumont Financial Partners LLC acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 736 shares of the biotechnology company’s stock, valued at approximately $206,000.
Other institutional investors have also modified their holdings of the company. Annapolis Financial Services LLC bought a new stake in Biogen in the fourth quarter valued at $25,000. Signet Investment Advisory Group Inc. acquired a new stake in shares of Biogen during the 4th quarter worth about $26,000. Sittner & Nelson LLC bought a new position in Biogen during the 4th quarter valued at about $28,000. Coastal Capital Group Inc. acquired a new position in Biogen in the first quarter valued at about $28,000. Finally, CVA Family Office LLC acquired a new position in Biogen in the first quarter valued at about $31,000. Institutional investors and hedge funds own 83.51% of the company’s stock.
Shares of NASDAQ BIIB opened at $280.21 on Monday. Biogen Inc. has a 52-week low of $223.25 and a 52-week high of $363.92. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.79 and a current ratio of 2.06. The stock has a market cap of $42.19 billion, a P/E ratio of 9.28, a P/E/G ratio of 1.04 and a beta of 0.53. The firm has a 50 day moving average price of $271.34 and a 200 day moving average price of $264.10.
Several research analysts have recently commented on BIIB shares. Wedbush boosted their target price on Biogen from $236.00 to $245.00 and gave the stock a “neutral” rating in a report on Monday, April 19th. SVB Leerink decreased their target price on Biogen from $430.00 to $380.00 and set an “outperform” rating on the stock in a report on Thursday, February 4th. Cantor Fitzgerald cut their price target on Biogen from $278.00 to $268.00 and set a “neutral” rating for the company in a report on Wednesday, February 17th. DZ Bank lowered shares of Biogen from a “buy” rating to a “hold” rating and set a $264.00 price objective on the stock. in a report on Friday, February 5th. Finally, Morgan Stanley lowered their price objective on shares of Biogen from $351.00 to $343.00 and set an “overweight” rating for the company in a research report on Monday, April 26th. Four research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $305.57.
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.